Shuwen Biotech Appoint Medical Professor of the University of Chicago to Advisory Board

Deqing, China, March 6, 2017 — Shuwen Biotech Co. Ltd announced that it had appointed Dr. Philip Connell, MD, a leading radiation oncologist to its advisory board.

Dr. Connell, a professor in the Radiation and Cellular Oncology Department of the University of Chicago School of Medicine, is a physician and an active cancer researcher. He has published numerous research papers in leading medical journals, and has received many research awards for his pioneering cancer research.

In 2014, Dr. Connell and his colleagues discovered a multi-gene expression signature and successfully developed an algorithm to calculate a Recombinant Proficiency Score (RPS) that reflects the proficiency of recombination DNA repair pathways in tumor cells and may predict tumor sensitivity to radiation therapy and chemotherapies including DNA-damaging agents and PARP inhibitors.

“We are very excited to have Dr. Connell as an advisor,” stated Jay Z Zhang, Chairman and CEO of Shuwen Biotech. “Dr. Connell’s expertise in oncology and personalized medicine will prove to be invaluable to us as Shuwen continues to expand its pipeline of innovative cancer diagnostics.”

About Shuwen Biotech Co. Ltd.

Based in China and led by U.S. diagnostic industry veterans, Shuwen Biotech is an integrated diagnostic company engaged in licensing, developing, marketing and distributing innovative products and services for disease diagnosis and personalized medicine. The company strives to provide China’s doctors and their patients with a comprehensive menu of the most innovative diagnostic products and services for improved disease prediction, screening, diagnosis, prognosis and treatment. Shuwen offers, in China, diagnostic kits and diagnostic services for disease prevention and personalized medicine in cancer and other diseases. More information about Shuwen Biotech Co. Ltd. can be found at